Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a ...
Novartis seeks to collaborate with Healthcare Professionals and Healthcare Organizations in interest of patients. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals ...
Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...
Welcome to the Novartis US Privacy Policy Center. Novartis Pharmaceuticals Corporation (“Novartis”, “we”, “our”, or “us”) is a United States-based ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Shareholders approve all other proposals by the Board of Directors, including the reduction of share capital, the 2025 report on nonfinancial matters and the 2025 Compensation Report, as well as the ...
Novartis Chief Digital Officer, Bertrand Bodson and Microsoft Healthcare Corporate Vice President, Peter Lee also discussed the potential of data science and AI during a recent visit to Novartis ...
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut ...
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra ®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface pain Deal consistent with Novartis focused strategy of ...
ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ）（以下「ノバルティス ファーマ」）は、本日、「プルヴィクト ® 静注」（一般名 ...
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results